Snesha Modi, MD
Internal Medicine · Evansville, INNPI 1366616435
Payments from drug & device makers
Across 260 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$820
- GSK$548
- Novo Nordisk$476
- Amgen$279
- Merck$236
- Lilly USA, LLC$177
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,994100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 65 | $820 |
| GSK | 34 | $548 |
| Novo Nordisk | 31 | $476 |
| Amgen | 19 | $279 |
| Merck | 15 | $236 |
| Lilly USA, LLC | 13 | $177 |
| AstraZeneca | 8 | $148 |
| Novartis | 9 | $138 |
| Boehringer Ingelheim | 8 | $125 |
| Travere Therapeutics, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 5 | $95 |
| Pfizer | 6 | $87 |
| Johnson & Johnson | 6 | $75 |
| Amarin Pharma, Inc. | 5 | $73 |
| Mylan Specialty L.p. | 2 | $63 |
| Astellas Pharma US Inc | 4 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $55 |
| Exact Sciences | 3 | $48 |
| Sumitomo Pharma America, Inc. | 3 | $47 |
| Corium, LLC | 4 | $43 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| Boston Scientific | 1 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Inspire Medical Systems, Inc. | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Abbott | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
How this compares
$3,994 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 82 | $70,073 |
| OzempicSemaglutide | 45 | $62,778 |
| JardianceEmpagliflozin | 42 | $46,434 |
| MounjaroTirzepatide | 29 | $33,126 |
| XareltoRivaroxaban | 36 | $30,624 |
| FarxigaDapagliflozin Propanediol | 37 | $30,606 |
| TrulicityDulaglutide | 17 | $29,009 |
| JanuviaSitagliptin Phosphate | 19 | $21,997 |
| MyrbetriqMirabegron | 40 | $19,445 |
| TradjentaLinagliptin | 26 | $15,271 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $14,031 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $11,732 |
| SynthroidLevothyroxine Sodium | 73 | $6,257 |
| Atorvastatin Calcium | 943 | $5,567 |
| Metoprolol Succinate | 372 | $5,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $87 | $71,44094 claims |
| Novo NordiskOzempic | $476 | $62,77845 claims |
| Lilly USA, LLCMounjaro, Trulicity | $177 | $62,13546 claims |
| Boehringer IngelheimJardiance, Tradjenta | $125 | $61,70468 claims |
| Johnson & JohnsonXarelto | $75 | $30,62436 claims |
| AstraZenecaFarxiga | $148 | $30,60637 claims |
| MerckJanuvia | $236 | $21,99719 claims |
| Astellas Pharma US IncMyrbetriq | $58 | $19,44540 claims |
| GSKBreo Ellipta | $548 | $14,03121 claims |
| AbbVieSynthroid | $820 | $6,25773 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Evansville
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.